The Catalyst
This week's two biggest single-name moves were both late-stage clinical trial failures: Alumis fell roughly 53% after its Phase 2b LUMUS trial of envudeucitinib missed both endpoints in lupus, and Ultragenyx fell roughly 47% after its Phase 3 Aspire trial of apazunersen failed in Angelman syndrome — together, real setbacks in two genuinely different disease areas landing in the same week. On the positive side, Summit Therapeutics rose after partner Akeso reported that ivonescimab beat Keytruda on overall survival in a head-to-head Phase III lung cancer trial, and Tarsus Pharmaceuticals gained on real data from its pending acquisition target, Alkeus. Biotech was roughly flat to modestly positive across market cap tiers this week; medtech lagged, with the micro-cap tier down over 2%.
Sector Performance by Market Cap
Biotech was roughly flat to modestly positive across market cap tiers this week, slightly trailing both XBI (+0.9%) and IBB (+1.4%). Medtech underperformed its own benchmark (XHE −0.8%), with the micro-cap tier down over 2%.
Grouped by lead asset disease category.
Top Gainers & Laggards
Gainers
Partner Akeso reported that ivonescimab demonstrated a statistically significant overall survival benefit versus Keytruda (pembrolizumab) monotherapy in the Phase III HARMONi-2 lung cancer trial — the fourth Phase III readout for the drug to hit its OS endpoint (Summit Therapeutics, 9/2).
Real Phase 3 data published in JAMA Ophthalmology for gildeuretinol — the lead asset of pending acquisition target Alkeus — showed the drug cut retinal lesion growth by 21.6% versus untreated patients in a 50-patient Stargardt disease trial.
Laggards
Phase 2b LUMUS trial of envudeucitinib missed its primary and secondary endpoints in the overall lupus population; a prespecified subgroup with high interferon gene signature showed robust responses, and the company plans to pursue Phase 3 in that biomarker-selected population (Alumis, 9/1).
Phase 3 Aspire trial of apazunersen (GTX-102) failed to meet its primary cognitive endpoint and key secondary endpoint in Angelman syndrome. Multiple analysts downgraded the stock; management is reviewing whether to continue the program.
Two other names showed larger raw % moves this week (ORGS, ONCO/GRI-class microcaps) but were excluded — extremely thin volume and real market caps under $10M make those moves unreliable signal, not real market-moving news.
This Week's Financing Activity
| Company | Stage | Amount | Type |
|---|---|---|---|
| Moderna (MRNA) | Public | $2.0B | Private Placement |
| Jazz Pharmaceuticals (JAZZ) | Public | $1.0B | Notes Offering (Debt) |
| Scan.com | Private | $220M | Financing |
| AusperBio | Private | $120M | Financing |
| Kazia Therapeutics (KZIA) | Public | $120M | Public Offering |
| Elucid | Private | $55M | Series D |
| N-Power Medicine | Private | $32M | Series B |
| Kardium | Private | $31M | Government Investment |
| Intelligent Bio Solutions (INBS) | Public | $15M | Financing |
| VolitionRx (VNRX) | Public | $9.9M | Convertible Notes |
The Week's Narrative
A Real Contender to Keytruda Clears Another Bar
Summit Therapeutics' partner Akeso reported that ivonescimab achieved a statistically significant overall survival benefit versus Merck's Keytruda in a head-to-head Phase III trial in first-line PD-L1-positive lung cancer — the fourth Phase III trial for the drug to hit its OS endpoint. The market's reaction was measured rather than euphoric: this result was largely anticipated after the same trial's progression-free survival win in 2024.
Two Real Late-Stage Failures, Two Different Lessons
Alumis's lupus trial missed its overall population endpoints but showed a real, robust signal in a prespecified biomarker-defined subgroup — a "the drug may still work, just not in everyone" outcome. Ultragenyx's Angelman trial missed cleanly, with no comparable silver lining disclosed, and management is now reviewing whether the program continues at all. Same week, same broad setback category, genuinely different paths forward.
This Week's Two Biggest Moves Were Both Trial Failures
Not a regulatory story this time — a clinical one. The week's two largest single-name declines both came from late-stage trials missing their endpoints, in two genuinely unrelated disease areas.
Alumis's lupus trial and Ultragenyx's Angelman trial failed in the same week, for different reasons and with different paths forward — a reminder that "late-stage biotech risk" isn't one uniform story, even when two real failures land together.